What is Leerink Partnrs’ Estimate for Immunome Q2 Earnings?

Immunome, Inc. (NASDAQ:IMNM) – Equities researchers at Leerink Partnrs lifted their Q2 2025 earnings per share estimates for shares of Immunome in a research report issued on Monday, May 12th. Leerink Partnrs analyst A. Berens now expects that the company will post earnings per share of ($0.59) for the quarter, up from their previous estimate of ($0.79). The consensus estimate for Immunome’s current full-year earnings is ($2.21) per share. Leerink Partnrs also issued estimates for Immunome’s Q3 2025 earnings at ($0.69) EPS, Q4 2025 earnings at ($0.79) EPS, FY2025 earnings at ($2.61) EPS, FY2026 earnings at ($2.64) EPS and FY2027 earnings at ($2.32) EPS.

Immunome (NASDAQ:IMNM) last issued its earnings results on Monday, May 12th. The company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.66) by $0.14. The company had revenue of $2.93 million during the quarter, compared to analyst estimates of $0.46 million. Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%.

Several other brokerages have also commented on IMNM. Lake Street Capital assumed coverage on Immunome in a research report on Wednesday, April 2nd. They issued a “buy” rating and a $23.00 target price for the company. Guggenheim decreased their target price on Immunome from $35.00 to $25.00 and set a “buy” rating for the company in a research report on Thursday, March 20th. Lifesci Capital assumed coverage on Immunome in a research report on Tuesday, March 11th. They issued an “outperform” rating and a $20.00 target price for the company. Wedbush restated an “outperform” rating and set a $21.00 price objective (down previously from $33.00) on shares of Immunome in a research report on Tuesday. Finally, Stephens restated an “overweight” rating and set a $30.00 price objective on shares of Immunome in a research report on Thursday, March 20th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $23.33.

Immunome Trading Up 0.4%

Shares of IMNM opened at $8.00 on Thursday. The firm has a market cap of $696.10 million, a price-to-earnings ratio of -0.99 and a beta of 2.00. The stock has a 50 day moving average of $7.66 and a 200-day moving average of $9.85. Immunome has a 52 week low of $5.15 and a 52 week high of $16.81.

Institutional Trading of Immunome

Several hedge funds have recently added to or reduced their stakes in the business. Redmile Group LLC raised its stake in Immunome by 11.0% during the 1st quarter. Redmile Group LLC now owns 5,361,187 shares of the company’s stock valued at $36,081,000 after acquiring an additional 533,161 shares in the last quarter. Velan Capital Investment Management LP bought a new stake in Immunome during the 1st quarter valued at $1,033,000. Driehaus Capital Management LLC bought a new stake in Immunome during the 1st quarter valued at $4,109,000. Rafferty Asset Management LLC raised its stake in Immunome by 25.9% during the 1st quarter. Rafferty Asset Management LLC now owns 102,475 shares of the company’s stock valued at $690,000 after acquiring an additional 21,084 shares in the last quarter. Finally, Corebridge Financial Inc. raised its stake in Immunome by 35.9% during the 1st quarter. Corebridge Financial Inc. now owns 34,735 shares of the company’s stock valued at $234,000 after acquiring an additional 9,179 shares in the last quarter. Institutional investors own 44.58% of the company’s stock.

Insider Activity at Immunome

In other Immunome news, CEO Clay B. Siegall bought 137,100 shares of the business’s stock in a transaction on Wednesday, March 26th. The shares were purchased at an average price of $7.29 per share, with a total value of $999,459.00. Following the purchase, the chief executive officer now directly owns 806,736 shares of the company’s stock, valued at approximately $5,881,105.44. The trade was a 20.47% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Jean Jacques Bienaime bought 7,000 shares of the business’s stock in a transaction on Monday, March 24th. The shares were acquired at an average cost of $8.21 per share, for a total transaction of $57,470.00. Following the purchase, the director now directly owns 23,615 shares in the company, valued at $193,879.15. This represents a 42.13% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased 156,400 shares of company stock worth $1,160,495 in the last 90 days. 8.60% of the stock is currently owned by company insiders.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.